Last reviewed · How we verify
Methylprednisolone Injection [Solu-Medrol]
Methylprednisolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Methylprednisolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Acute exacerbations of multiple sclerosis, Cerebral edema.
At a glance
| Generic name | Methylprednisolone Injection [Solu-Medrol] |
|---|---|
| Also known as | Lidocaine, 1% solution |
| Sponsor | Mercy Health Ohio |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Oncology (supportive care) |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone acts as a glucocorticoid receptor agonist, translocating to the nucleus to modulate gene expression of inflammatory mediators. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses T-cell proliferation and antibody production. This broad immunosuppressive and anti-inflammatory effect makes it useful across multiple inflammatory and autoimmune conditions.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Acute exacerbations of multiple sclerosis
- Cerebral edema
- Severe allergic reactions
- Adrenocortical insufficiency
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (euphoria, depression)
- Immunosuppression / increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
- Hypokalemia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: